Lv1
18 积分 2024-10-03 加入
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Therapeutic potential of cis-targeting bispecific antibodies
1个月前
已完结
In-Depth Structure and Function Characterization of Heterogeneous Interchain Cysteine-Conjugated Antibody–Drug Conjugates
1个月前
已完结
皖公网安备34019202002308
